NZ537840A - Modafinil polymorphic forms and methods for their preparation - Google Patents
Modafinil polymorphic forms and methods for their preparationInfo
- Publication number
- NZ537840A NZ537840A NZ537840A NZ53784003A NZ537840A NZ 537840 A NZ537840 A NZ 537840A NZ 537840 A NZ537840 A NZ 537840A NZ 53784003 A NZ53784003 A NZ 53784003A NZ 537840 A NZ537840 A NZ 537840A
- Authority
- NZ
- New Zealand
- Prior art keywords
- modafinil
- crl
- solvate
- powder
- diffraction pattern
- Prior art date
Links
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title claims abstract description 388
- 229960001165 modafinil Drugs 0.000 title claims abstract description 238
- 238000000034 method Methods 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- 239000012453 solvate Substances 0.000 claims description 123
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 69
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 66
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 59
- 239000002904 solvent Substances 0.000 claims description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 52
- 239000006104 solid solution Substances 0.000 claims description 36
- 239000000243 solution Substances 0.000 claims description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 34
- 239000007787 solid Substances 0.000 claims description 28
- 238000010438 heat treatment Methods 0.000 claims description 25
- 238000003756 stirring Methods 0.000 claims description 25
- 238000002425 crystallisation Methods 0.000 claims description 22
- 208000035475 disorder Diseases 0.000 claims description 22
- 238000001914 filtration Methods 0.000 claims description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 21
- 238000001816 cooling Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 230000008025 crystallization Effects 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 18
- 238000004807 desolvation Methods 0.000 claims description 17
- 208000032140 Sleepiness Diseases 0.000 claims description 16
- 206010041349 Somnolence Diseases 0.000 claims description 16
- 230000037321 sleepiness Effects 0.000 claims description 16
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims description 15
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 239000013078 crystal Substances 0.000 claims description 13
- 238000001704 evaporation Methods 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 10
- 230000008020 evaporation Effects 0.000 claims description 10
- 201000003631 narcolepsy Diseases 0.000 claims description 10
- 206010016256 fatigue Diseases 0.000 claims description 9
- 206010020765 hypersomnia Diseases 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- QBKFLYWZRMHHRS-UHFFFAOYSA-N chloroform;1,4-dioxane Chemical compound ClC(Cl)Cl.C1COCCO1 QBKFLYWZRMHHRS-UHFFFAOYSA-N 0.000 claims description 7
- NWSBNVVOFKKFNV-UHFFFAOYSA-N chloroform;oxolane Chemical compound ClC(Cl)Cl.C1CCOC1 NWSBNVVOFKKFNV-UHFFFAOYSA-N 0.000 claims description 7
- 208000016255 tiredness Diseases 0.000 claims description 7
- 230000003867 tiredness Effects 0.000 claims description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 5
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims description 5
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims description 5
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000002490 cerebral effect Effects 0.000 claims description 5
- 208000037765 diseases and disorders Diseases 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 208000013403 hyperactivity Diseases 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 238000010899 nucleation Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 201000002859 sleep apnea Diseases 0.000 claims description 5
- 208000019116 sleep disease Diseases 0.000 claims description 5
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 4
- 206010012218 Delirium Diseases 0.000 claims description 4
- 229940035676 analgesics Drugs 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 239000002948 appetite stimulant Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 208000015114 central nervous system disease Diseases 0.000 claims description 4
- 230000003920 cognitive function Effects 0.000 claims description 4
- 230000003001 depressive effect Effects 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000036651 mood Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 208000001797 obstructive sleep apnea Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 19
- 239000011541 reaction mixture Substances 0.000 description 19
- 238000010992 reflux Methods 0.000 description 19
- 238000004090 dissolution Methods 0.000 description 16
- 241000282472 Canis lupus familiaris Species 0.000 description 12
- 229940079593 drug Drugs 0.000 description 9
- 230000036470 plasma concentration Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 238000002441 X-ray diffraction Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 206010000117 Abnormal behaviour Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000007605 air drying Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- -1 "iloroform Chemical compound 0.000 description 2
- 238000004438 BET method Methods 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 101100114828 Drosophila melanogaster Orai gene Proteins 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000003869 acetamides Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- MSWIFFGHKBTPMY-VFUQPONKSA-L magnesium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O MSWIFFGHKBTPMY-VFUQPONKSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/06—Separation; Purification; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40206402P | 2002-08-09 | 2002-08-09 | |
| US10/635,445 US6992219B2 (en) | 2002-08-09 | 2003-08-07 | Modafinil polymorphic forms |
| PCT/IB2003/003215 WO2004014846A1 (en) | 2002-08-09 | 2003-08-08 | Modafinil polymorphic forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ537840A true NZ537840A (en) | 2007-01-26 |
Family
ID=31720568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ537840A NZ537840A (en) | 2002-08-09 | 2003-08-08 | Modafinil polymorphic forms and methods for their preparation |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6992219B2 (https=) |
| EP (2) | EP1575915A1 (https=) |
| JP (2) | JP4718177B2 (https=) |
| CN (3) | CN100506790C (https=) |
| AU (1) | AU2003253128B2 (https=) |
| CA (4) | CA2804385A1 (https=) |
| IL (3) | IL166301A (https=) |
| MX (1) | MXPA05001506A (https=) |
| NZ (1) | NZ537840A (https=) |
| WO (1) | WO2004014846A1 (https=) |
| ZA (1) | ZA200500411B (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ2003529A3 (cs) | 2000-07-27 | 2003-09-17 | Teva Pharmaceutical Industries Ltd. | Krystalický a čistý modafinil a postup jeho přípravy |
| JP4498679B2 (ja) * | 2001-03-27 | 2010-07-07 | 大日本住友製薬株式会社 | 結晶性イソキサゾール誘導体およびその医薬製剤 |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| FR2849029B1 (fr) | 2002-12-20 | 2005-03-18 | Lafon Labor | Procede de preparation et formes cristallines des enantiomeres optiques du modafinil. |
| US7244865B2 (en) * | 2003-02-24 | 2007-07-17 | Mallinckrodt Inc. | Process for preparing benzhydrylthioacetamide |
| WO2004083183A1 (en) * | 2003-03-21 | 2004-09-30 | Hetero Drugs Limited | Novel crystalline forms of aripiprazole |
| US20050154052A1 (en) * | 2003-03-24 | 2005-07-14 | Hetero Drugs Limited | Novel crystalline forms of (s)-citalopram oxalate |
| US7504516B2 (en) * | 2003-03-27 | 2009-03-17 | Hetero Drugs Limited | Crystalline forms of candesartan cilexetil |
| AU2003230195A1 (en) * | 2003-04-02 | 2004-10-25 | Hetero Drugs Limited | A novel process for amorphous form of donepezil hydrochloride |
| US7560560B2 (en) * | 2003-04-16 | 2009-07-14 | Hetero Drugs Limited | Crystalline forms of donepezil hydrochloride |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| ES2330321T3 (es) | 2003-05-16 | 2009-12-09 | Cephalon France | Procedimiento de sintesis de modafinilo. |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| PT1673370E (pt) | 2003-10-16 | 2009-11-05 | Symed Labs Ltd | Forma cristalina de linezolida |
| US20090018202A1 (en) * | 2004-02-06 | 2009-01-15 | Cephalon, Inc. | Modafinil compositions |
| EP2292213A1 (en) * | 2004-02-06 | 2011-03-09 | Cephalon, Inc. | Compositions comprising a polymorphic form of armodafinil |
| WO2005099822A2 (en) * | 2004-04-13 | 2005-10-27 | Cephalon, Inc. | Reduction of drug / drug interactions with modafinil |
| WO2005099353A2 (en) * | 2004-04-19 | 2005-10-27 | Symed Labs Limited | A novel process for the preparation of linezolid and related compounds |
| EP1755388B1 (en) * | 2004-05-28 | 2010-10-06 | Transform Pharmaceuticals, Inc. | Mixed co-crystals and pharmaceutical compositions comprising the same |
| CA2701710C (en) | 2004-07-20 | 2013-08-27 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| US20060235008A1 (en) | 2004-08-19 | 2006-10-19 | Hetero Drugs Limited | Novel polymorphs of efavirenz |
| CA2614777C (en) * | 2005-07-21 | 2012-04-17 | Neurohealing Pharmaceuticals, Inc. | Rapid onset and short term modafinil compositions and methods of use thereof |
| US7518019B2 (en) * | 2006-06-01 | 2009-04-14 | Hetero Drugs Limited | Processes for preparing sertraline hydrochloride crystalline forms |
| KR20090031618A (ko) * | 2006-07-12 | 2009-03-26 | 엘란 코포레이션, 피엘씨 | 나노입자형 모다피닐 제제 |
| EP2056811B8 (en) * | 2006-08-14 | 2018-03-21 | Neurohealing Pharmaceuticals, Inc. | Modafinil-based treatment for premature ejaculation |
| UA110598C2 (uk) | 2006-11-10 | 2016-01-25 | Басф Се | Спосіб одержання кристалічної модифікації фіпронілу |
| US8791046B2 (en) | 2006-11-10 | 2014-07-29 | Basf Se | Crystalline modification of fipronil |
| JP5931322B2 (ja) | 2006-11-10 | 2016-06-08 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | フィプロニルの結晶変態 |
| WO2008068767A2 (en) * | 2006-12-07 | 2008-06-12 | Hetero Drugs Limited | A novel crystalline form of lansoprazole |
| CN101641090B (zh) * | 2006-12-19 | 2012-12-05 | 亚勒斯有限公司 | 莫达非尼在制备治疗多动腿综合征的药物中的应用 |
| US20100234468A1 (en) * | 2007-06-04 | 2010-09-16 | Abhay Gaitonde | Novel process |
| FR2923482B1 (fr) * | 2007-11-09 | 2010-01-29 | Servier Lab | Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| US8741329B2 (en) * | 2007-09-21 | 2014-06-03 | Merck Sharp & Dohme B.V. | Drug delivery system |
| US20090105346A1 (en) * | 2007-10-02 | 2009-04-23 | Alexandr Jegorov | Novel crystalline forms of armodafinil and preparation thereof |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| US10596103B2 (en) | 2013-12-11 | 2020-03-24 | Merek Sharp & Dohme B.V. | Drug delivery system for delivery of anti-virals |
| US10413504B2 (en) | 2013-12-11 | 2019-09-17 | Merck Sharp & Dohme Corp. | Intravaginal ring drug delivery system |
| US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
| EP4210709B1 (en) * | 2020-09-14 | 2025-10-29 | Pharma Cinq, LLC | 2',3'-diacetyluridine substituted with acetoacetyl at the 5' position |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1520812A (en) * | 1975-10-02 | 1978-08-09 | Lafon Labor | Benzhydrylsulphinyl derivatives |
| GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| FR2663225B1 (fr) | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| FR2684875B1 (fr) | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
| FR2697162B1 (fr) | 1992-10-23 | 1995-01-13 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux. |
| FR2706767B1 (https=) * | 1993-06-22 | 1995-09-08 | Lafon Labor | |
| FR2707637B1 (fr) | 1993-06-30 | 1995-10-06 | Lafon Labor | Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique. |
| US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| FR2771004B1 (fr) * | 1997-11-19 | 2000-02-18 | Inst Curie | Utilisation de derives de benzhydryl sulfinyle pour la fabrication de medicaments ayant un effet eveillant dans des situations de troubles de la vigilance d'origine medicamenteuse |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| IL128989A0 (en) | 1999-03-15 | 2000-02-17 | Popov Sergey | Safety trocar assembly |
| US6346548B1 (en) * | 1999-08-16 | 2002-02-12 | Cephalon, Inc. | Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue |
| US6455588B1 (en) * | 1999-08-20 | 2002-09-24 | Cephalon, Inc. | Compositions including modafinil for treatment of eating disorders and for appetite stimulation |
| US20030180352A1 (en) | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| FR2804322B1 (fr) * | 2000-01-31 | 2002-04-19 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament destine a corriger les troubles de la vigilance associes aux myopathies |
| US6492396B2 (en) * | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| CZ2003529A3 (cs) * | 2000-07-27 | 2003-09-17 | Teva Pharmaceutical Industries Ltd. | Krystalický a čistý modafinil a postup jeho přípravy |
| US6489363B2 (en) * | 2000-10-11 | 2002-12-03 | Cephalon, Inc. | Pharmaceutical solutions of modafinil compounds |
| CZ2004446A3 (cs) | 2001-09-07 | 2005-01-12 | Teva Pharmaceutical Industries Ltd. | Krystalické formy valaciklovir hydrochloridu |
| US6875893B2 (en) * | 2002-05-23 | 2005-04-05 | Cephalon, Inc. | Preparations of a sulfinyl acetamide |
| US6992219B2 (en) | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| US20040242698A1 (en) | 2003-05-13 | 2004-12-02 | Cephalon Inc. | Analeptic and antidepressant combinations |
| US20040229941A1 (en) | 2003-05-13 | 2004-11-18 | Cephalon, Inc. | Analeptic and antidepressant combinations |
| AR045423A1 (es) | 2003-05-13 | 2005-10-26 | Cephalon Inc | Combinaciones de analiticos y antidepresivos |
| AR045314A1 (es) | 2003-05-13 | 2005-10-26 | Cephalon Inc | Composiciones farmaceuticas de analepticos y antidepresivos |
| US20040229943A1 (en) | 2003-05-16 | 2004-11-18 | Cephalon Inc | Analeptic and drug combinations |
| ES2330321T3 (es) | 2003-05-16 | 2009-12-09 | Cephalon France | Procedimiento de sintesis de modafinilo. |
-
2003
- 2003-08-07 US US10/635,445 patent/US6992219B2/en not_active Expired - Fee Related
- 2003-08-08 NZ NZ537840A patent/NZ537840A/en not_active IP Right Cessation
- 2003-08-08 MX MXPA05001506A patent/MXPA05001506A/es active IP Right Grant
- 2003-08-08 EP EP03784340A patent/EP1575915A1/en not_active Withdrawn
- 2003-08-08 CA CA2804385A patent/CA2804385A1/en not_active Abandoned
- 2003-08-08 CA CA2494010A patent/CA2494010C/en not_active Expired - Fee Related
- 2003-08-08 CN CNB038190850A patent/CN100506790C/zh not_active Expired - Fee Related
- 2003-08-08 WO PCT/IB2003/003215 patent/WO2004014846A1/en not_active Ceased
- 2003-08-08 EP EP11171058A patent/EP2402311A1/en not_active Withdrawn
- 2003-08-08 CA CA2746788A patent/CA2746788C/en not_active Expired - Fee Related
- 2003-08-08 CN CN201210395545.8A patent/CN102875429B/zh not_active Expired - Fee Related
- 2003-08-08 AU AU2003253128A patent/AU2003253128B2/en not_active Ceased
- 2003-08-08 CN CN2012103955547A patent/CN102875430A/zh active Pending
- 2003-08-08 CA CA2840721A patent/CA2840721C/en not_active Expired - Fee Related
- 2003-08-08 JP JP2004527153A patent/JP4718177B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-13 IL IL166301A patent/IL166301A/en not_active IP Right Cessation
- 2005-01-17 ZA ZA2005/00411A patent/ZA200500411B/en unknown
- 2005-10-12 US US11/248,442 patent/US7405323B2/en not_active Expired - Fee Related
-
2007
- 2007-12-14 US US11/956,877 patent/US7649020B2/en not_active Expired - Fee Related
-
2010
- 2010-10-20 JP JP2010235766A patent/JP5307106B2/ja not_active Expired - Fee Related
- 2010-12-13 IL IL209966A patent/IL209966A/en not_active IP Right Cessation
- 2010-12-13 IL IL209965A patent/IL209965A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2494010C (en) | Modafinil polymorphic forms | |
| TWI782976B (zh) | （s）－阿弗索拉納（afoxolaner）之晶型 | |
| EP1772456A1 (en) | Novel crystalline polymorphs of clopidogrel | |
| JP2015508090A (ja) | 固体形態のダビガトランエテキシレートメシレート及びその調製方法 | |
| CN101896477A (zh) | 硝克柳胺化合物五种晶型、其制法和其药物组合物与用途 | |
| JP2004526706A (ja) | オクスカルバゼピンの新しい結晶形態及びそれらの調製方法 | |
| JP6908657B2 (ja) | ４−［２−ジメチルアミノ−１−（１−ヒドロキシシクロヘキシル）エチル］フェニル４−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用 | |
| CN101619033B (zh) | 莫达非尼多晶型 | |
| CN118984818A (zh) | 环己酮化合物的晶型 | |
| AU2008200919A1 (en) | Novel crystalline polymorphs of clopidogrel | |
| HK1192222A1 (zh) | 莫达非尼光学对映异构体的晶形及其制备方法 | |
| HK1192222B (en) | Preparation method and crystalline form of optical enantiomers of modafinil | |
| WO2013103004A1 (ja) | （２ｅ）－３－（１ｈ－インダゾール－３－イル）－ｎ－（３－メトキシフェニル）－ｎ－［３－（メチルスルホニル）プロピル］ブト－２－エンアミドの結晶形 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: CEPHALON FRANCE, FR Free format text: OLD OWNER(S): CEPHALON FRANCE; ORGANISATION DE SYNTHESE MONDIALE ORSYMONDE |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 AUG 2016 BY DENNEMEYER + CO Effective date: 20130725 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 08 AUG 2023 BY DENNEMEYER + CO Effective date: 20140823 |
|
| ASS | Change of ownership |
Owner name: TEVA SANTE, FR Effective date: 20151022 |
|
| EXPY | Patent expired |